Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II signal finding study of AEVI-002 in severe pediatric patients with Crohn's Disease who previously failed treatment with an Anti-TNFa inhibitor

Next Previous
Trial Profile

A Phase I/II signal finding study of AEVI-002 in severe pediatric patients with Crohn's Disease who previously failed treatment with an Anti-TNFa inhibitor

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quisovalimab (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Proof of concept; Therapeutic Use

    • Most Recent Events

    • 08 Mar 2021 According to a Cerecor media release, initial data is expected in the second quarter
    • 01 Nov 2018 According to an Aevi Genomic Medicine media release, the Company has not yet enrolled any patients into this trial and expects to enrol a small number of patients by the end of the first quarter of 2019. Initial data is expected by mid-year 2019.
    • 13 Mar 2018 According to an Aevi Genomic Medicine media release, the company is initiating three additional sites in an effort to enhance enrollment and data expected by year-end 2018.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top